The lawsuit, filed by Robbins Geller Rudman & Dowd LLP in the Northern District of California, accuses PROCEPT BioRobotics and its executives of violating the Securities Exchange Act. According to the complaint, the company incentivized customers to place bulk orders exceeding actual procedure demand, effectively pulling future revenue forward to bolster financial reports. This practice allegedly resulted in over 10,000 excess units sitting in field inventory by the end of the class period.

The company's stock faced multiple sharp declines as the situation unfolded. Following an August 2025 earnings call where executives signaled lower-than-expected shipments and eliminated the Chief Commercial Officer role, the stock price dropped approximately 16%. Further revelations in November 2025 regarding inventory mismanagement led to another 10% decline. The final blow came in February 2026, when the firm disclosed that handpiece sales had consistently outpaced procedures since early 2023, triggering an 18% slide in share value. Investors seeking to participate in the litigation may contact attorneys Ken Dolitsky or Michael Albert at Robbins Geller.